Doris is 85 and suffers from moisture build up in her eye, what some call wet eye. She is on Medicare and gets treated with Eylea, a Regeneron product, every 4-5 weeks. Each treatment costing $6,200. That is more than $70,000 per year even though Doris never made more than $40,000 while working. … Continue reading Regeneron’s Eylea: Pulling Open the Curtain on Drug Costs
Tag: investments
In a front page story Sunday May 20, 2012, Ted Sickinger of the Oregonian provided a detailed review of private equity valuation concerns. This portfolio of opaque investments has grown substantially and poses unique risks to Oregonian PERS participants. In his article, Sickinger notes this analysis is based upon original Parish & Company research. Although … Continue reading The Oregonian Reports on Valuation Concerns Regarding PERS Private Equity Investments